STAT+: Element Biosciences, an Illumina rival, on its genomics ambitions — and why it hasn’t gone public
Element Biosciences' modest growth comes at a time when some other players are struggling in a sequencer market dominated by Illumina.
SAN DIEGO — Companies racing to read the genome accurately, quickly, and affordably have hit a snag recently, with several firms
